News | Interventional Radiology | June 19, 2019

Merit Medical Acquires Brightwater Medical Inc.

Acquisition brings Brightwater’s ConvertX system for treating severe obstructions of the ureter into Merit portfolio

Merit Medical Acquires Brightwater Medical Inc.

June 19, 2019 — Merit Medical Systems Inc. announced it has acquired Brightwater Medical Inc., based in Temecula, Calif. Brightwater Medical’s primary product, the ConvertX, is a single device used to replace a series of interventional radiology devices and procedures used to treat severe obstructions of the ureter.

The transaction consists of a $35 million upfront payment and potential earn-out payments of up to $15 million based on receipt of CE mark approval and achievement of future sales targets.

Brightwater Medical was founded by Robert Smouse, M.D., professor of radiology and surgery, University of Illinois College of Medicine. The ConvertX system is designed to be implanted once and converted from a nephroureteral catheter to a nephroureteral stent without requiring sedation or local anesthesia. Brightwater Medical recently received U.S. Food and Drug Administration (FDA) clearance for the ConvertX biliary stent system.

Merit Medical Chairman and CEO Fred P. Lampropoulos said the ConvertX system complements Merit’s Resolve drainage catheter portfolio and potentially drives pull-through of other Merit products such as InQwire guide wires, Advocate PTA balloons and other vascular products.

Over the next several months, Merit Medical intends to maintain Brightwater Medical’s production capabilities in Temecula while duplicating those capabilities in its catheter facility in Pearland, Texas, prior to transferring the ConvertX manufacturing operations to its Pearland facility.

For more information: www.merit.com

Related Content

Adept Medical Launches Antegrade IR Platform
Technology | Interventional Radiology | September 03, 2019
New Zealand-based Adept Medical announced the launch of the Antegrade IR Platform. Clinically driven, it is placed to...
Study Finds Growth in Paracentesis and Thoracentesis Procedures

Image source: Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. [CC BY 3.0 (https://creativecommons.org/licenses/by/3.0)]

News | Interventional Radiology | August 27, 2019 | Jeff Zagoudis, Associate Editor
A new Harvey L. Neiman Health Policy Institute study assesses temporal and patient-level differences in paracentesis...
Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Boston Scientific Closes Acquisition of BTG plc
News | Interventional Radiology | August 20, 2019
Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
FDA Clears NvisionVLE Imaging System for Pancreatic and Biliary Applications

Image courtesy of NinePoint Medical

Technology | Interventional Radiology | August 14, 2019
August 14, 2019 — NinePoint Medical Inc. announced it has received U.S.
International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere
News | Interventional Radiology | July 31, 2019
New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have...
WVU Medicine Installs First Alphenix 4D CT in the U.S.
News | CT Angiography (CTA) | July 24, 2019
The West Virginia University (WVU) Heart and Vascular Institute is the first hospital in the country to acquire the...
Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...